Therapeutically targeting type I interferon directly to XCR1+ dendritic cells reveals the role of cDC1s in anti-drug antibodies

Therapeutically targeting type I interferon directly to XCR1+ dendritic cells reveals the role of cDC1s in anti-drug antibodies

Conventional type 1 dendritic cells (cDC1s) are superior in antigen cross-presentation and priming CD8+ T cell anti-tumor immunity and thus, are a target of high interest for cancer immunotherapy. Type I interferon (IFN) is a potent inducer of antigen cross-presentation, but, unfortunately, shows on...

Full description

Bibliographic Details
Main Authors: Paul Noe, Joy H. Wang, Kyu Chung, Zhiyong Cheng, Jessica J. Field, Xiaomeng Shen, Christa L. Cortesio, Cinthia V. Pastuskovas, Hyewon Phee, Kristin V. Tarbell, Jackson G. Egen, Amy-Jo Casbon
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Immunology
Subjects:
immunogenicity
interferon
immunotherapy
dendritic cells
conventional type I DCs
antibody IFN fusion
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1272055/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1272055/full

Similar Items